This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Atrial fibrillation (AF) and coronaryarterydisease are frequently associated and, when so, lead to a grim prognosis. Notwithstanding, in contrast with the attention dedicated to the management of antithrombotic treatment, research on other aspects of coronaryarterydisease in AF is only recently gaining traction.
Using intravascular imaging (IVI) to guide stent implantation during complex stenting procedures is safer and more effective for patients with severely calcified coronaryarterydisease than conventional angiography, the more commonly used technique.
Drug-eluting stents (DES) play a crucial role in treating coronaryarterydisease (CAD) by preventing restenosis. These stents are coated with drug carriers that release antiproliferative drugs within the vessel. Our author analysis identifies Patrick W.
In patients with unprotected left main coronaryarterydisease (ULMCAD), this study compared the long-term prognosis of drug-eluting stent insertion guided by intravascular ultrasonography (IVUS) vs. angiography.
We aimed to perform a systematic review and meta-analysis to study the effects of colchicine in patients with symptomatic coronaryarterydisease (CAD) who have undergone PCI. These results were driven mainly by the reduction in repeat vessel revascularisation, stroke and stent thrombosis.
This narrative review discusses drug-coated balloon angioplasty as an alternative to drug-eluting stent for percutaneous coronary intervention in patients with in-stent restenosis and de novo coronaryarterydisease.
Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronaryarterydisease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue. vs. 28.7%; P=0.006).
The pullback pressure gradient is a novel index that discriminates focal from diffuse coronaryarterydisease based on fractional flow reserve pullbacks. The mean minimum stent area was 5.69±1.99 mm2and was significantly larger in vessels with focal disease (6.18±2.12 Fractional flow reserve before PCI was 0.65±0.14,
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronaryarterydisease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.
Introduction The use of contemporary drug-eluting stents (DES) has significantly improved outcomes of patients with coronaryarterydisease (CAD) undergoing percutaneous coronary intervention (PCI). years, Diabetes mellitus 29%, acute coronary syndrome 67%, chronic total occlusion 9%). Of these, 40.9%
The goal of the INFINITY-SWEDEHEART trial was to compare the efficacy of the DynamX bioadaptor, a novel coronary implantable device, to a contemporary drug-eluting stent (DES) in the treatment of coronaryarterydisease requiring percutaneous coronary intervention (PCI).
BackgroundCoronary arterydisease is a global health concern that necessitates treatments, such as percutaneous coronary intervention (PCI) with drug-eluting stents (DES). QCA and OCT were used to evaluate the lumen diameter, cross-sectional areas and stent apposition or coverage.
Smits and a distinguished team of international researchers, the trial compares the performance of SMT's biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the biodegradable-polymer Ultimaster Tansei * stent in patients with high bleeding risk (HBR) undergoing abbreviated dual antiplatelet therapy (DAPT).
Hes team have recently developed a new CoronaryArtery Tree description and Lesion EvaluaTion (CatLet) angiographic scoring system, which is capable of accounting for the variability in coronary anatomy, and.
Despite target lesion revascularization (TLR) being a known occurrence after percutaneous coronary intervention (PCI) for unprotected left main coronaryartery (LMCA) disease, uncertainties persist regarding its timing and impact on long-term mortality. Original article: Kim et al. J Am Coll Cardiol Intv 2024;17:32–42.
Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronaryarterydisease, and antiplatelet therapy after coronarystenting. Too Many Choices?
Background Kounis syndrome is an acute coronary syndrome (ACS) caused by allergic reactions, including coronaryartery spasm (type I) caused by allergies without coronary predisposing factors, pre-existing coronary atherosclerosis, and coronaryarterydisease.
This breakthrough device is poised to significantly change the approach to treating coronary CTOs by providing real-time optical coherence tomography (OCT) visualization, enabling precise guidewire placement within the target vessel's true lumen and subsequent revascularization.
That, it was possible to treat atherosclerotic coronaryarterydisease with an updated Andreas Grüntzig’s balloon alone, without the safety net and comfort of implanting a single stent. It was unprecedented, going against received wisdom.
The newly CE launched Freesolve RMS for coronaryartery lesions, based on the BIOmag magnesium alloy and the proven Orsiro drug-eluting stent (DES) coating technology, provides safety, improved deliverability, and optimal performance and vessel support during and after implantation.2,3 2,3 It has shown 99.6%
The longstanding benefits of percutaneous angioplasty and stenting in coronaryarterydisease, where atherosclerosis is the overarching cause in nearly all cases, provided a compelling rationale for exploring similar interventions in intracranial atherosclerotic stenosis.
The near-immediate or instant feedback learning process by which the heart responds to any new invasive procedural variation facilitates each new change; be it drug-eluting stent, drug-coated balloon, or both in different combinations and permutations.
An 80-year-old man with renal disease on hemodialysis, coronaryarterydisease, complete heart block and a dual chamber leadless pacemaker (LP) implanted because of previous bacteremia, presented with syncope. An echocardiogram showed newly reduced left ventricular ejection fraction of 30-35%.
Understanding the impact of mechanical forces on blood vessels holds the potential for developing shear-regulated drugs, improving diagnostics, and informing clinical decision-making in coronary atherosclerosis management.
Self-reported adherence to cardiovascular medications in patients who have coronaryarterydisease is for the combination of aspirin, beta-blocker and a lipid-lowering agent in surveys.7 Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in CoronaryArteryDisease. J Am Geriatr Soc.
Clinicians need better tools to guide decision making on the choice of antiplatelet therapy in coronaryarterydisease patients, particularly after coronarystenting. "This study highlights the power of our cell mimic platform in driving next-generation tests that could enhance patient care."
Old ‘NSTEMI’ A history of coronaryarterydisease and a stent to the same territory further increases pre-test likelihood of acute coronary occlusion, including in-stent thrombosis. The patient had a history of ‘NSTEMI’ a decade prior, with an RCA stent. Does this change your interpretation?
Coronaryartery bypass surgery (CABG) has been a cornerstone in the treatment of coronaryarterydisease (CAD), providing a lifeline for individuals with blocked or narrowed arteries.
Patients usually have a normal life expectancy unless other structural heart diseases are present. After guidewire crossing, balloon angioplasty was performed, and a drug-eluting stent was deployed. Introduction:Dextrocardia is a rare congenital condition where the heart's apex points to the right, with an incidence of about 0.01%.
vs. 52.1%), coronaryarterydisease (25.3% Acute stenting was not associated with improved functional outcome at 90-days (aOR 0.86, 95% CI 0.41-1.82, Patients with tandem lesions were more likely to be men (60.6% vs. 46.6%,), have hyperlipidemia (60.9% vs. 19.0%), smokers (35.9% vs. 16.8%), all p<0.05.
Importantly, all of the participants had recently undergone percutaneous coronary intervention (PCI) — a surgical procedure in which a stent is placed in a coronaryartery to open up a blockage. All of the participants had stable coronaryarterydisease and were on lipid-lowering therapies during the study.
Baseline patient demographics and clinical characteristics recorded include age, gender, HbA1C level, National Institutes of Health Stroke Scale (NIHSS) at admission, manual CT ASPECTS and stroke risk factors (hypertension, atrial fibrillation, coronaryarterydisease, congestive heart failure, LDL, smoking, history of stroke/TIAs).
By Magnus Nossen, edits by Grauer and Smith The patient is a 70-something female with DMII, HTN and an extensive prior history of coronaryarterydisease and myocardial infarctions. At that visit the patient was found to have an in-stent RCA occlusion. She's had multiple PCI procedures. Troponin I peaked at 18.323ng/L.
Introduction:Inflammation plays an important role in the pathogenesis of coronaryarterydisease and Acute Coronary Syndrome (ACS). All patients had interventional PCI with balloon and stent insertion. Circulation, Volume 150, Issue Suppl_1 , Page A4125093-A4125093, November 12, 2024.
Introduction:Subacute stent thrombosis (ST) is related to high rates of cardiac reinfarction. The patient’s chest pain (CP) was not alleviated with initial revascularization of his left circumflex (LCx) ST, requiring PCI to his right coronaryartery (RCA) chronic total occlusion (CTO). We present a case of reinfarction from ST.
So the presence of an open artery does not tell you anything about the state of the artery at the time of the ECG. Angiogram: Severe two-vessel coronaryarterydisease with possible co-culprits (90% proximal circumflex, 70% mid/distal RCA) in the setting of non-ST elevation myocardial infarction.
Intra-procedural data included access route, coronary anatomy, lesion complexity, number of stents deployed, door-to-balloon time for primary PCI, and any intra-procedural complications. and the average number of stents 2.6. The radial approach was used in 544/567 (95.94%), the average SYNTAX score was 34.8 ± 9.6,
You can easily imagine this patient getting one of several diagnoses -- vasospasm, MINOCA , pericarditis, or maybe even no diagnosis at all beyond "non-obstructive coronaryarterydisease." The operator documented thoughtful consideration of risks and benefits of stent placement.
A 56 year old male with a history of diabetes, dyslipidemia, hypertension, and coronaryarterydisease presented to the emergency department with sudden onset weakness, fatigue, lethargy, and confusion. RAO Caudal View Post PCI This is the RAO Caudal view after thrombectomy and stent placement.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content